Methadone in post-herpetic neuralgia: A pilot proof-of-concept study

OBJECTIVE: This research was designed as a pilot proof-of-concept study to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line post-herpetic neuralgia treatments and had indications for adding an opioid agent to their current drug regimens. METHODS: This cross-over study was double blind and placebo controlled. Ten opioid naïve post-herpetic neuralgia patients received either methadone (5 mg bid) or placebo for three weeks, followed by a 15-day washout period and a second three-week treatment with either methadone or placebo, accordingly. Clinical evaluations were performed four times (before and after each three-week treatment period). The evaluations included the visual analogue scale, verbal category scale, daily activities scale, McGill pain questionnaire, adverse events profile, and evoked pain assessment. All patients provided written informed consent before being included in the study. ClinicalTrials.gov: NCT01752699 RESULTS: Methadone, when compared to placebo, did not significantly affect the intensity of spontaneous pain, as measured by the visual analogue scale. The intensity of spontaneous pain was significantly decreased after the methadone treatment compared to placebo on the category verbal scale (50% improved after the methadone treatment, none after the placebo, p = 0.031). Evoked pain was reduced under methadone compared to placebo (50% improved after the methadone treatment, none after the placebo, p = 0.031). Allodynia reduction correlated with sleep improvement (r = 0.67, p = 0.030) during the methadone treatment. The side effects profile was similar between both treatments. Conclusions: Methadone seems to be safe and efficacious in post-herpetic neuralgia. It should be tried as an adjunctive treatment for post-herpetic neuralgia in larger prospective studies.

Saved in:
Bibliographic Details
Main Authors: Teixeira,Manoel J., Okada,Massako, Moscoso,Ana Sofia Cueva, Puerta,Mariana Yumi Takahashi, Yeng,Lin T., Galhardoni,Ricardo, Tengan,Sérgio, Andrade,Daniel Ciampi de
Format: Digital revista
Language:English
Published: Faculdade de Medicina / USP 2013
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322013000701057
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1807-59322013000701057
record_format ojs
spelling oai:scielo:S1807-593220130007010572015-11-26Methadone in post-herpetic neuralgia: A pilot proof-of-concept studyTeixeira,Manoel J.Okada,MassakoMoscoso,Ana Sofia CuevaPuerta,Mariana Yumi TakahashiYeng,Lin T.Galhardoni,RicardoTengan,SérgioAndrade,Daniel Ciampi de Post-Herpetic Neuralgia Methadone Neuropathic Pain OBJECTIVE: This research was designed as a pilot proof-of-concept study to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line post-herpetic neuralgia treatments and had indications for adding an opioid agent to their current drug regimens. METHODS: This cross-over study was double blind and placebo controlled. Ten opioid naïve post-herpetic neuralgia patients received either methadone (5 mg bid) or placebo for three weeks, followed by a 15-day washout period and a second three-week treatment with either methadone or placebo, accordingly. Clinical evaluations were performed four times (before and after each three-week treatment period). The evaluations included the visual analogue scale, verbal category scale, daily activities scale, McGill pain questionnaire, adverse events profile, and evoked pain assessment. All patients provided written informed consent before being included in the study. ClinicalTrials.gov: NCT01752699 RESULTS: Methadone, when compared to placebo, did not significantly affect the intensity of spontaneous pain, as measured by the visual analogue scale. The intensity of spontaneous pain was significantly decreased after the methadone treatment compared to placebo on the category verbal scale (50% improved after the methadone treatment, none after the placebo, p = 0.031). Evoked pain was reduced under methadone compared to placebo (50% improved after the methadone treatment, none after the placebo, p = 0.031). Allodynia reduction correlated with sleep improvement (r = 0.67, p = 0.030) during the methadone treatment. The side effects profile was similar between both treatments. Conclusions: Methadone seems to be safe and efficacious in post-herpetic neuralgia. It should be tried as an adjunctive treatment for post-herpetic neuralgia in larger prospective studies. info:eu-repo/semantics/openAccessFaculdade de Medicina / USPClinics v.68 n.7 20132013-07-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322013000701057en10.6061/clinics/2013(07)25
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Teixeira,Manoel J.
Okada,Massako
Moscoso,Ana Sofia Cueva
Puerta,Mariana Yumi Takahashi
Yeng,Lin T.
Galhardoni,Ricardo
Tengan,Sérgio
Andrade,Daniel Ciampi de
spellingShingle Teixeira,Manoel J.
Okada,Massako
Moscoso,Ana Sofia Cueva
Puerta,Mariana Yumi Takahashi
Yeng,Lin T.
Galhardoni,Ricardo
Tengan,Sérgio
Andrade,Daniel Ciampi de
Methadone in post-herpetic neuralgia: A pilot proof-of-concept study
author_facet Teixeira,Manoel J.
Okada,Massako
Moscoso,Ana Sofia Cueva
Puerta,Mariana Yumi Takahashi
Yeng,Lin T.
Galhardoni,Ricardo
Tengan,Sérgio
Andrade,Daniel Ciampi de
author_sort Teixeira,Manoel J.
title Methadone in post-herpetic neuralgia: A pilot proof-of-concept study
title_short Methadone in post-herpetic neuralgia: A pilot proof-of-concept study
title_full Methadone in post-herpetic neuralgia: A pilot proof-of-concept study
title_fullStr Methadone in post-herpetic neuralgia: A pilot proof-of-concept study
title_full_unstemmed Methadone in post-herpetic neuralgia: A pilot proof-of-concept study
title_sort methadone in post-herpetic neuralgia: a pilot proof-of-concept study
description OBJECTIVE: This research was designed as a pilot proof-of-concept study to evaluate the use of low-dose methadone in post-herpetic neuralgia patients who remained refractory after first and second line post-herpetic neuralgia treatments and had indications for adding an opioid agent to their current drug regimens. METHODS: This cross-over study was double blind and placebo controlled. Ten opioid naïve post-herpetic neuralgia patients received either methadone (5 mg bid) or placebo for three weeks, followed by a 15-day washout period and a second three-week treatment with either methadone or placebo, accordingly. Clinical evaluations were performed four times (before and after each three-week treatment period). The evaluations included the visual analogue scale, verbal category scale, daily activities scale, McGill pain questionnaire, adverse events profile, and evoked pain assessment. All patients provided written informed consent before being included in the study. ClinicalTrials.gov: NCT01752699 RESULTS: Methadone, when compared to placebo, did not significantly affect the intensity of spontaneous pain, as measured by the visual analogue scale. The intensity of spontaneous pain was significantly decreased after the methadone treatment compared to placebo on the category verbal scale (50% improved after the methadone treatment, none after the placebo, p = 0.031). Evoked pain was reduced under methadone compared to placebo (50% improved after the methadone treatment, none after the placebo, p = 0.031). Allodynia reduction correlated with sleep improvement (r = 0.67, p = 0.030) during the methadone treatment. The side effects profile was similar between both treatments. Conclusions: Methadone seems to be safe and efficacious in post-herpetic neuralgia. It should be tried as an adjunctive treatment for post-herpetic neuralgia in larger prospective studies.
publisher Faculdade de Medicina / USP
publishDate 2013
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322013000701057
work_keys_str_mv AT teixeiramanoelj methadoneinpostherpeticneuralgiaapilotproofofconceptstudy
AT okadamassako methadoneinpostherpeticneuralgiaapilotproofofconceptstudy
AT moscosoanasofiacueva methadoneinpostherpeticneuralgiaapilotproofofconceptstudy
AT puertamarianayumitakahashi methadoneinpostherpeticneuralgiaapilotproofofconceptstudy
AT yenglint methadoneinpostherpeticneuralgiaapilotproofofconceptstudy
AT galhardoniricardo methadoneinpostherpeticneuralgiaapilotproofofconceptstudy
AT tengansergio methadoneinpostherpeticneuralgiaapilotproofofconceptstudy
AT andradedanielciampide methadoneinpostherpeticneuralgiaapilotproofofconceptstudy
_version_ 1756432212226473984